Switzerland-based Helsinn Healthcare has obtained US Food and Drug Administration approval for its fixed combination capsule Akynzeo to treat patients with chemotherapy-induced nausea and vomiting (CINV).

Akynzeo is a combination of netupitant and and palonosetron, which targets two critical signaling pathways associated with CINV.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Helsinn’s Group CEO Riccardo Braglia said: "Helsinn is delighted with the FDA approval of Akynzeo and we look forward to a successful launch in the US.

"We are proud of our long-standing partnership with Eisai and Akynzeo is the newest development in our combined efforts."

"The approval of Akynzeo represents an important development in the prevention of acute nausea and vomiting for patients."

The approval was based on data from Phase II and Phase III clinical studies of Akynzeo in patients undergoing treatment with moderately and highly emetogenic chemotherapy regimens for various tumor types.

See Also:

In June 2010, Eisai had signed a licensing agreement with Helsinn for Akynzeo. Based on the agreement, the US subsidiaries of both companies will market the product in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Eisai CEO Yuji Matsue said: "The approval of Akynzeo represents an important development in the prevention of acute and delayed nausea and vomiting for patients."

Both companies are also developing an injectable formulation to further maximise the value of Akynzeo.

Earlier this year, European Medicines Agency (EMA) started to review the submission of Helsinn’s marketing authorisation application for netupitant/palonosetron fixed combination for the prevention of acute and delayed CINV.